Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, no par value per share
-
Shares outstanding
-
112,245,592
-
Total 13F shares
-
90,513,054
-
Share change
-
-1,715,694
-
Total reported value
-
$1,351,320,799
-
Put/Call ratio
-
98%
-
Price per share
-
$14.93
-
Number of holders
-
213
-
Value change
-
-$31,137,056
-
Number of buys
-
117
-
Number of sells
-
100
Institutional Holders of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) as of Q4 2023
As of 31 Dec 2023,
NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) was held by
213 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
90,513,054 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, Capital International Investors, BlackRock Inc., BAILLIE GIFFORD & CO, STATE STREET CORP, Capital World Investors, PRICE T ROWE ASSOCIATES INC /MD/, TWO SIGMA ADVISERS, LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
213
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.